DVAX Dynavax Technologies Corporatio

+0  (3%)
Previous Close 5.65
Open 5.70
Price To book 2.44
Market Cap 257.24M
Shares 44,352,000
Volume 1,510,256
Short Ratio 3.14
Av. Daily Volume 1,378,310

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 1Q 2017.
Head and neck squamous-cell carcinoma cancer
Phase 2 part of trial to be initiated 1Q 2017.
SD-101 + Pembrolizumab
Melanoma - cancer
Phase 1/2 data presented at ASH 2016.
Low-grade, B cell lymphoma
CRL February 25, 2013 and November 14, 2016. New PDUFA August 10, 2017. Advisory Committee Meeting July 28, 2017.
Hepatitis B
Phase 2 enrolling as of early 2017.

Latest News

  1. ETFs with exposure to Dynavax Technologies Corp. : April 21, 2017
  2. William Blair Assigns 70% Probability of Approval to Dynavax's Heplisav
  3. What Dynavax Technologies Holders Need to Consider Heading Into the Heplisav-B PDUFA
  4. Why Dynavax Technologies Corporation Stock Briefly Spiked Today
  5. Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
  6. ETFs with exposure to Dynavax Technologies Corp. : March 27, 2017
  7. Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017
  8. Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting
  9. Dynavax Technologies reports 4Q loss
  10. Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update
  11. 3 Beaten Down Stocks Ready to Bounce Back
  12. The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
  13. UPDATE: Dynavax shares reverse premarket losses to open flat
  14. Dynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the International Congress on Targeted Anticancer Therapies
  15. Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Dynavax Technologies and Lexicon Pharmaceuticals
  16. Dynavax to Present at the Cowen and Company 37th Annual Health Care Conference
  17. Here’s What’s Next For Lexicon Pharmaceuticals, Inc. (LXRX) And Dynavax Technologies Corporation (DVAX)
  18. Dynavax stock surges 53% on new FDA review of Hep B vaccine and Trump statements about FDA deregulation
  19. 4 Biopharma Stocks Moving the Market on Wednesday